Renal Denervation: The Latest Data and Implications for Clinical Practice-Renal Denervation: The Latest Data and Implications for Clinical Practice

Renal Denervation: The Latest Data and Implications for Clinical Practice

Video Transcription

Video Summary

The webinar on renal denervation discussed the latest data and implications for clinical practice. The speakers included Dr. Michael Fisher, who provided an overview of the burden of hypertension in the VA community, as well as the prevalence of hypertension among active duty personnel and veterans. He highlighted that hypertension is common among veterans and is getting more common over time. Dr. Chandan Devareddy discussed the various approaches to renal denervation, including radiofrequency-based systems, ultrasound-based systems, and alcohol-mediated renal denervation. He presented data from the Spiral HTN Clinical Program and the Radiance HTN Clinical Trial Program, which showed that renal denervation can lower blood pressure in both on-med and off-med patients. Dr. Vasilios Papadimitriou discussed the VA's approach to hypertension management, including telehealth, frequent appointments, and involving primary care physicians. He also talked about the promise and limitations of renal denervation, noting that it is most effective as an adjunct therapy to drug therapy. Overall, the webinar provided valuable insights into the current understanding and application of renal denervation in the management of hypertension.

Keywords

webinar

renal denervation

latest data

clinical practice

hypertension

veterans

approaches to renal denervation

lower blood pressure

VA's approach to hypertension management

adjunct therapy